Polymorphism in drug substances is a phenomenon that leads to a change in the efficacy of drugs due to changes in their physicochemical properties, particularly solubility and bioavailability. Glimepiride has two polymorphs described in the literature Glimepiride form I and Glimepiride form II.A new crystalline form-III was prepared by recrystallization from a Glimepiride form-I by using an N-methyl-2-pyrrolidone solvent system and ethyl acetate and acetone solvent mix 50/50 v/v. The solubility and melting properties of the novel polymorph are significantly different from the reported two polymorphs. A novel polymorph has been evaluated by using an X-ray diffractometer and differential scanning calorimeter, Thermogravimetric techniques, and image analysis. The crystal structure of Glimepiride form III is more thermodynamically stable than the previously reported form I and form II. A new crystalline form of glimepiride with a characteristic melting point of 276.2°C, a distinguished marker 2θpeak at 6.7°, 30.5°, and marker peak of form I and II in the region of 2θ 8-12.5 not observed in diffractogram of novel Glimepiride polymorph III which resulting in a unique Diffractogram pattern of form III.IR spectra show that the absorption band shows at 3325.28cm-1 which is different than reported for Glimepiride polymorph I absorption at 3290 and 3370 cm-1 and for Glimepiride form II absorption at 3370 and 3100 cm-1